| pubmed-article:2162749 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2162749 | lifeskim:mentions | umls-concept:C0033429 | lld:lifeskim |
| pubmed-article:2162749 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2162749 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:2162749 | lifeskim:mentions | umls-concept:C0205464 | lld:lifeskim |
| pubmed-article:2162749 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2162749 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:2162749 | lifeskim:mentions | umls-concept:C0599278 | lld:lifeskim |
| pubmed-article:2162749 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2162749 | pubmed:dateCreated | 1990-7-31 | lld:pubmed |
| pubmed-article:2162749 | pubmed:abstractText | Propafenone is a class 1c antiarrhythmic agent with moderate beta-blocking activity as a result of a structural similarity to beta-adrenoceptor antagonists. In a randomized, double-blind crossover exercise study, eight healthy volunteers were examined before and 2 1/2 hours after oral administration of 300 mg (R,S)-, 150 mg (R)-, and 150 mg (S)-propafenone hydrochloride. The mean rate pressure product was significantly reduced by (R,S)-propafenone hydrochloride (-5.2%; p = 0.045) and half-dosed (S)-propafenone hydrochloride (-5.9%; p = 0.013), whereas the (R)-enantiomer caused no significant changes. There was a significant difference between the effects of (R)- and (S)-propafenone (p = 0.033). In beta-adrenoceptor-binding inhibition experiments with (S)-(125I)iodocyanopindolol in a sarcolemma-enriched cardiac membrane preparation, the eudismic ratio of (S)- over (R)-propafenone was 54. On the spontaneously beating Langendorff-perfused guinea pig heart, 3 x 10(-6) mol/L of both (R)- and (S)-propafenone resulted in significant changes (p less than 0.01) on His bundle conduction (+79% +/- 27% and +69% +/- 9%), as well as comparable decreases in the maximal rate of pacing with 1:1 conduction of the atrial (-54% +/- 10% and -57% +/- 8%) and ventricular myocardium (-42% +/- 6% and -43% +/- 6%), indicating equal effects in sodium channel-dependent antiarrhythmic class 1 activity. Thus (R)- and (S)-propafenone exert different beta-blocking actions but equal effects on the sodium channel-dependent antiarrhythmic class 1 activity. More specific antiarrhythmic class 1 therapy with reduction of beta-blocking side effects may be attained with optically pure (R)-propafenone hydrochloride instead of the currently used racemic mixture. | lld:pubmed |
| pubmed-article:2162749 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2162749 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2162749 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2162749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2162749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2162749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2162749 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2162749 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2162749 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:2162749 | pubmed:issn | 0009-9236 | lld:pubmed |
| pubmed-article:2162749 | pubmed:author | pubmed-author:KleinWW | lld:pubmed |
| pubmed-article:2162749 | pubmed:author | pubmed-author:StarkGG | lld:pubmed |
| pubmed-article:2162749 | pubmed:author | pubmed-author:LindnerWW | lld:pubmed |
| pubmed-article:2162749 | pubmed:author | pubmed-author:ZernigGG | lld:pubmed |
| pubmed-article:2162749 | pubmed:author | pubmed-author:StoschitzkyKK | lld:pubmed |
| pubmed-article:2162749 | pubmed:author | pubmed-author:StarkUU | lld:pubmed |
| pubmed-article:2162749 | pubmed:author | pubmed-author:GraziadeiII | lld:pubmed |
| pubmed-article:2162749 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2162749 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:2162749 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2162749 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2162749 | pubmed:pagination | 740-6 | lld:pubmed |
| pubmed-article:2162749 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:meshHeading | pubmed-meshheading:2162749-... | lld:pubmed |
| pubmed-article:2162749 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2162749 | pubmed:articleTitle | Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies. | lld:pubmed |
| pubmed-article:2162749 | pubmed:affiliation | Department of Medicine, Karl Franzens University, Graz, Austria. | lld:pubmed |
| pubmed-article:2162749 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2162749 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2162749 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2162749 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2162749 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2162749 | lld:pubmed |
